Tutti gli studi
ReclutamentoFASE3INTERVENTISTICO

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

The REMAP-CAP study is looking at the best ways to treat adults who are very unwell with lung infections such as severe pneumonia, the flu, or COVID-19, and need care in an intensive care unit (ICU). It's a special type of study that allows doctors to test many different treatments at the same time to see which ones are most effective. This flexible design means the study can quickly adapt to new information, helping doctors make better decisions about care. The goal is to improve how patients recover from these serious illnesses. This study can also quickly adapt to new health crises, like a pandemic, to find treatments for new viruses.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE3
Sponsor
UMC Utrecht
Obiettivo di iscrizione
20,000
Inizio
11 Apr 2016
Completamento stimato
01 Feb 2028

Di cosa tratta questo studio?

When someone is very ill with a serious lung infection, like severe pneumonia, the flu, or COVID-19, they often need to be looked after in an intensive care unit (ICU). In the ICU, doctors use many different treatments to help patients get better and fight off the infection. While doctors know many treatments are helpful, it's not always clear which combination works best for different people.

This study, called REMAP-CAP, is designed to help doctors figure out the most effective ways to treat these severe lung infections. It's a clever type of study that can test many different treatments all at once. What's more, it's 'adaptive', meaning it can learn from the patients already in the study. This helps the study identify promising treatments faster and direct new patients towards the treatments that seem to be working best.

The main aim is to improve how patients recover from these serious lung infections. It also acts like a flexible research 'platform' that can quickly start looking for treatments if a new widespread illness, like a pandemic, emerges. This means it can rapidly respond to new health challenges and continue to find the best care for patients.

Punti chiave

  • Targets severe lung infections like pneumonia, flu, and COVID-19.
  • Aims to find the best combinations of existing treatments.
  • Can test many treatments at once and adapt quickly.
  • Helps improve care for very unwell patients in intensive care.
  • Can rapidly respond to new health crises, like pandemics.

Chi può essere idoneo?

Generally, to join the main REMAP-CAP study, you need to be an adult (18 or over) admitted to an intensive care unit (ICU) because of a severe lung infection, like pneumonia, within two days of getting to the hospital. Your doctors would have seen signs of a lung infection and scans showing changes in your lungs. You would also need support for your organs, such as help with breathing or medication to support your blood pressure.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 18 anni o più?
  2. Have you been admitted to intensive care for a severe lung infection?
  3. Did you come to the ICU within 48 hours of being admitted to the hospital?
  4. Do you need support for breathing or blood pressure in the ICU?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you are asked to join this study, it means your doctors believe you could benefit from it. You would continue to receive the best care for your condition, and the study would involve trying different combinations of existing treatments. This includes various medicines for infection, inflammation, or to prevent blood clots. There are no extra hospital visits or special appointments as part of the study; all monitoring would happen as part of your usual intensive care. The study aims to understand the best treatment approaches and would continue for as long as you need intensive care, with doctors monitoring your progress carefully.

Rischi e benefici potenziali

The main benefit of taking part is that you would receive care based on the latest knowledge and could potentially receive a treatment combination that is more effective for your condition. As the study uses existing, approved medications, the risks are generally similar to those you would face with standard intensive care. However, any medication can have side effects, and your doctors would monitor you closely for these. You, or your legal representative, have the right to withdraw from the study at any time without affecting your medical care.

Locations (408)

  • University of Florida
    Codice postale verificato
    Jacksonville, Stati Uniti· Reclutamento
  • Augusta University
    Codice postale verificato
    Augusta, United States· Non ancora in fase di reclutamento
  • University of Illinois Health
    Codice postale verificato
    Chicago, Stati Uniti· Reclutamento
  • Tulane Medical Center
    Codice postale verificato
    New Orleans, Stati Uniti· Non ancora in fase di reclutamento
  • Università del Michigan
    Codice postale verificato
    Ann Arbor, Stati Uniti· Reclutamento
  • Centro Oncologico Memorial Sloan Kettering
    Codice postale verificato
    New York, Stati Uniti· Reclutamento
  • Wake Forest Baptist Health
    Codice postale verificato
    Winston-Salem, Stati Uniti· Non ancora in fase di reclutamento
  • The Ohio State University Wexner Medical Center
    Codice postale verificato
    Columbus, Stati Uniti· Reclutamento
  • Oregon Health and Science University
    Codice postale verificato
    Portland, Stati Uniti· Reclutamento
  • University of Pittsburgh Medical Centre
    Codice postale verificato
    Pittsburgh, United States· Reclutamento
  • Brown University - Rhode Island Hospital
    Codice postale verificato
    Providence, Stati Uniti· Non ancora in fase di reclutamento
  • Canberra Hospital
    Codice postale verificato
    Canberra, Australia· Reclutamento

Domande comuni

What kind of infections does this study look at?

It looks at serious lung infections like pneumonia, the flu, and severe COVID-19 that require intensive care.

Why is this study different from others?

It can test many treatments at once and adapt quickly, learning from patients already in the study to find better treatments faster.

Riceverò un trattamento speciale se mi unisco?

You will receive the best possible care, and the study helps doctors choose the most effective combination of existing treatments for you.

Will I have to pay for anything?

No, all care and treatments related to the study are part of your hospital care and involve no extra cost to you.

Posso abbandonare lo studio se cambio idea?

Yes, you or your family can decide to withdraw from the study at any time. Your medical care will not be affected.

Come saperne di più

Cameron Green, MSc

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Randomized, Embedded, Multifactorial Adaptive Platform Trial…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.